Uso del prodotto: Questo prodotto è destinato esclusivamente alla ricerca.
Tutte le informazioni sui prodotti presenti su questo sito hanno scopo esclusivamente educativo. Qualsiasi forma di introduzione nel corpo di esseri umani o animali è severamente vietata dalla legge. Questo prodotto deve essere maneggiato solo da professionisti abilitati e qualificati. Non è un farmaco, un alimento o un cosmetico e non deve essere etichettato, utilizzato o presentato come tale.
IGF-1 LR3 1mg
Durante il cambio di confezione potresti ricevere prodotti con l’etichetta precedente o con quella nuova. Formulazione, purezza e qualità restano esattamente le stesse, secondo i nostri standard.
- Carta di credito
- Bonifico bancario (SEPA istantaneo)
- Bonifico bancario (ACH)
- Wise
- Revolut
- Zelle
- Remitly
- Western Union
- Chime
- Altri metodi
-25% su tutto – fino al 31 Ottobre
25% sui prezzi ordinari, in sostituzione degli altri saldi. Cumulabile solo con lo sconto crypto.
Spedizione in giornata per gli ordini USA effettuati entro le 12:00 EST.
Vedi le condizioni di spedizione →Ogni lotto è testato per purezza, potenza e qualità.
Vedi i risultati di laboratorio →IGF-1 LR3 (Long Arg3-IGF-1) is a synthetic 83-amino-acid analogue of insulin-like growth factor 1, engineered with an N-terminal 13-amino-acid extension and an Arg3 substitution that together confer markedly reduced affinity for IGF-binding proteins (IGFBPs) and extended plasma half-life. These modifications preserve IGF-1 receptor (IGF-1R) agonist activity while reducing IGFBP sequestration, enabling sustained receptor engagement in preclinical research models.
- High Purity – 99% Purity Guaranteed
- Independently Lab Tested
- Research Grade Quality
- For Laboratory Research Use Only
| Chemical Formula | C400H625N111O115S9 |
|---|---|
| Synonyms | Long R3-IGF-1, M9L22Y19H9, 143045-27-6, Long-(arg3)insulin-like growth factor-i |
| Molar Mass | 9,117.60 g/mol |
| CAS Number | 143045-27-6 |
| PubChem CID | N/A |
| Total Compound Content | 1 mg per vial |
| Shelf Life | 36 months |
Results refer to the tested sample. Check the batch and date in the report.
Why does IGF-1 LR3 have a longer half-life than native IGF-1?
Native IGF-1 is rapidly sequestered in circulation by IGF-binding proteins (IGFBPs 1–6), which extend its half-life but also restrict bioavailability. The Arg3 substitution and N-terminal 13-residue extension in IGF-1 LR3 reduce IGFBP affinity by approximately 1,000-fold, preventing this sequestration.
Without IGFBP binding, IGF-1 LR3 remains in free, receptor-accessible form for 56–72 hours — substantially longer than native IGF-1's 10–20-minute half-life when not IGFBP-bound.
Which intracellular signalling pathways does IGF-1 LR3 activate via IGF-1R?
IGF-1R is a receptor tyrosine kinase. Ligand binding drives receptor autophosphorylation, IRS-1/IRS-2 adapter recruitment, and activation of two primary downstream cascades: PI3K/Akt/mTOR (governing protein synthesis, glucose uptake, and cell survival) and MAPK/ERK (regulating cell proliferation and differentiation). Both pathways are fully engaged by IGF-1 LR3 at the IGF-1R, identical to native IGF-1.
What types of experimental programs are most suited to the IGF-1 LR3 10-vial KIT format?
The IGF-1 LR3 KIT format is particularly useful for longitudinal investigations, multi-arm experimental designs, concentration-response studies, receptor-signaling experiments, and pathway-characterization programs that require repeated compound preparation over extended periods.
The availability of multiple matched-batch vials supports consistent experimental conditions across separate study phases, treatment groups, and sampling timepoints. This makes the KIT format well-suited to research involving IGF-1 receptor signaling, PI3K/Akt/mTOR pathway analysis, MAPK/ERK pathway investigation, and comparative insulin-like growth factor pharmacology.
